Modulators of calcitonin and amylin activity
In various aspects, the present invention relates to novel compounds, which modulate calcitonin and amylin receptor activity; to processes for the preparation of such compounds; and to pharmaceutical compositions including such compounds. Compounds of the invention are useful as calcitonin and/or amylin agonists and in the treatment of bone disease such as osteoporosis, Paget's disease, hypercalcemia, and in the treatment of metabolic diseases, such as insulin-requiring states.
1 . A compound having formula I,
stereoisomers thereof, tautomers thereof, solvates thereof, and pharmaceutically acceptable salts thereof; wherein
A is —NH—CR 3a R 3b — wherein the NH is attached to the carbon bearing B, or A is —CRR′—CR 4a R 4b —CRR′—;
B is O or S;
X is N or NO;
Y is a divalent substituted or unsubstituted aryl, heterocyclyl, or cycloalkyl group;
Z is —C(O)OR 5 , —C(O)NR 6 R 7 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 6 R 7 , —C(O)R 5 , —NR 6 R 7 , —OR 8 , —SO 2 NR 6 R 7 , —NR 6 SO 2 R 5 or —S(O) m R 5 ;
R and R′ at each occurrence are independently H or an unsubstituted C 1-3 alkyl group;
R 1 is H, —C(O)OR 9 , —C(O)NR 10 R 11 , —CN, —C(O)R 9 or —NR 10 C(O)R 9 ;
R 2 is —(C 1-2 alkyl)-R 12 wherein the C 1-2 alkyl is substituted or unsubstituted;
R 3a is a C 2-3 alkyl group, optionally substituted with one or more F;
R 3b is H or a C 2-3 alkyl group, optionally substituted with one or more F;
R 4a and R 4b are each independently —H, or substituted or unsubstituted C 1-6 alkyl;
R 5 is a substituted or unsubstituted aralkyl, heteroaralkyl, heterocyclylalkyl, alkyl-cycloalkyl, fused cycloalkylaryl, or fused heterocyclylaryl group;
R 6 and R 7 are each independently —H or a substituted or unsubstituted aralkyl, heteroaralkyl, heterocyclylalkyl, alkyl-cycloalkyl, fused cycloalkylaryl, or fused heterocyclylaryl group; or R 6 and R 7 , when attached to the same atom, together form a substituted or unsubstituted heterocyclyl group;
R 8 is a substituted or unsubstituted, branched or unbranched C 2-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 7-10 aralkyl group;
R 9 is —H or a substituted or unsubstituted alkyl, heteroalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group;
R 10 and R 11 are each independently —H or a substituted or unsubstituted alkyl, heteroalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl group; or R 10 and R 11 , when attached to the same atom, together form a substituted or unsubstituted heterocyclyl group;
R 12 is a substituted or unsubstituted cycloalkyl, aryl or heteroaryl group or an unsubstituted alkyl group; and
m is 0, 1 or 2.
2 . The compound of claim 1 wherein A is —NH—CR 3a R 3b —.
3 . The compound of claim 1 wherein B is O.
4 . The compound of claim 1 wherein X is N.
5 . The compound of claim 1 wherein Y is a divalent substituted or unsubstituted aryl or heterocyclyl group.
6 . The compound of claim 1 wherein Y is a divalent aryl or heteroaryl group.
7 . The compound of claim 1 wherein Y is a divalent phenyl group.
8 . The compound of claim 1 wherein Z is —C(O)OR 5 , —C(O)NR 6 R 7 , —NR 6 C(O)R 5 , —C(O)R 5 , —OR 8 , —SO 2 NR 6 R 7 , —NR 6 R 7 SO 2 R 5 or —S(O) m R 5 .
9 . The compound of claim 1 wherein Z is —C(O)OR 5 , —C(O)NR 6 R 7 , or —OR 8 .
10 . The compound of claim 1 wherein R 1 is H, —C(O)OR 9 or —C(O)NR 10 R 11 .
11 . The compound of claim 1 wherein R 9 , R 10 and R 11 are each independently —H, methyl, ethyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopentyl, or allyl.
12 . The compound of claim 1 wherein R 2 is —CH 2 —CH 2 —R 12 .
13 . The compound of claim 1 wherein R 12 is cyclohexyl, cyclopentyl, phenyl, 4-fluorophenyl, 4-trifluorophenyl, isobutyl or t-butyl.
14 . The compound of claim 1 having the Formula II:
15 . The compound of claim 14 wherein Z is —C(O)OR 5 , —C(O)NR 6 R 7 , or —OR 8 .
16 . The compound of claim 1 having the Formula III:
17 . The compound of claim 16 wherein Z is —C(O)OR 5 , —C(O)NR 6 R 7 , or —OR 8 .
18 . A compound of claim 1 wherein the compound is
2-[2-(4-Fluoro-phenyl)-ethyl]-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
4-{2-[2-(4-Fluoro-phenyl)-ethyl]-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl}-N-furan-2-ylmethyl-benzamide,
2-[2-(4-Fluoro-phenyl)-ethyl]-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid methyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid allyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid isopropyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid butyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid cyclopentyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid propyl ester,
2-(2-Cyclohexyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid isobutyl ester,
4-{4-[(Furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-2-[2-(4-trifluoromethyl-phenyl)-ethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-(4-Fluoro-benzyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
4-{4-[(Furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-2-phenethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-[2-(4-Fluoro-phenyl)-ethyl]-4-[4-(indan-1-ylcarbamoyl)-phenyl]-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-[2-(4-Fluoro-phenyl)-ethyl]-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-methyl-5-oxo-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester,
(S)-7-Ethyl-2-[2-(4-fluoro-phenyl)-ethyl]-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-(2-Cyclopentyl-ethyl)-4-{4-[(furan-2-ylmethyl)-carbamoyl]-phenyl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-[2-(4-Fluoro-phenyl)-ethyl]-7-isopropyl-5-oxo-4-{4-[(pyridin-3-ylmethyl)-carbamoyl]-phenyl}-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
4-(4-tert-Butoxy-phenyl)-2-[2-(4-fluoro-phenyl)-ethyl]-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester
4-[4-(4-Fluoro-benzyloxy)-phenyl]-2-[2-(4-fluoro-phenyl)-ethyl]-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
4-[2-(2-Cyclohexyl-ethyl)-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl]-N-furan-2-ylmethyl-benzamide,
(S)-2-[2-(4-Fluoro-phenyl)-ethyl]-4-{6-[(furan-2-ylmethyl)-carbamoyl]-pyridin-3-yl}-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-(2-Cyclohexyl-ethyl)-4-[4-(indan-1-ylcarbamoyl)-phenyl]-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
2-(2-Cyclohexyl-ethyl)-4-[4-(3,4-difluoro-benzylcarbamoyl)-phenyl]-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylic acid ethyl ester,
N-Furan-2-ylmethyl-4-(7-isopropyl-5-oxo-2-phenethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-benzamide, or
4-[(S)-2-(2-Cyclohexyl-ethyl)-7-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl]-N-indan-1-yl-benzamide.
19 . A method of preparing a compound of claim 1 wherein A is —NH—CR 3a R 3b — and X is N, the method comprising exposing a compound of formula IV
to a first oxidant that selectively oxidizes a dihydropyridinyl ring to a pyridinyl ring, thereby providing a compound of formula IA
wherein Z, Y, R 1 , R 2 , R 3a , and R 3b are as defined previously.
20 - 32 . (canceled)
33 . A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
34 . A method of treating a disorder mediated by a calcitonin or amylin receptor, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
35 . The method of claim 34 wherein the compound is a calcitonin or amylin receptor agonist.
36 . The method of claim 34 wherein the disorder is osteoporosis, Paget's disease, hypercalcemia, Sudeck's atrophy, polystatic fibrous displasia, intersemocostoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or defect, osteolytic bone disease, metastatic bone disorder, bone loss resulting from malignancy, endocrine disorder, autoimmune arthritides, breakage and fracture, or immobility and disuse, osteopathic pain, phantom limb pain, general pain, hyperalgesia, pain associated with diabetic neuropathy, insulin dependent diabetes, non-insulin dependent diabetes, impaired glucose tolerance, obesity, syndrome X, diabetic complications, primary or secondary hyperthyroidism, conditions associated with inhibiting gastric secretion, gastrointestinal disorders, renal osteodystrophy, obesity, or male infertility.
37 . A method of treating a bone disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
38 . The method of claim 37 wherein the bone disorder is osteoporosis, Paget's disease, hypercalcemia, Sudeck's atrophy, polystatic fibrous displasia, intersemocostoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or defect, osteolytic bone disease, metastatic bone disorder, bone loss resulting from malignancy, autoimmune arthritides, breakage and fracture, or immobility and disuse.
39 . The method of claim 37 wherein the bone disorder is osteoporosis or Paget's disease.
40 . A method of treating pain, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
41 . The method of claim 40 wherein the pain is osteopathic pain, phantom limb pain, general pain, hyperalgesia, or pain associated with diabetic neuropathy.
42 . A method of treating a metabolic disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
43 . The method of claim 42 wherein the metabolic disorder is insulin dependent diabetes, non-insulin dependent diabetes, impaired glucose tolerance, obesity, syndrome X, diabetes mellitus, hypoglycemia or an insulin-requiring disorder other than diabetes mellitus or diabetic complications.
44 . A method of modulating the activity of a calcitonin or amylin receptor comprising contacting the calcitonin or amylin receptor with a compound of claim 1 .
45 . The method of claim 44 wherein the compound is an agonist at the calcitonin or amylin receptor.
46 . The method of claim 43 wherein the compound is administered in combination with an insulin for the treatment of diabetes mellitus or an insulin-requiring disorder other than diabetes mellitus.
47 . The method of claim 43 wherein the compound is administered in combination with a glucagon for the treatment of hypoglycemia.